New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges

 
• By Derrick Gingery
  
Team reorganization
The OTAT renaming and reorganization will allow more flexibility for future growth. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies